Table 2.
Animal model | Inserted stent | Purposes | Results | Refs |
| ||||
Healthy rabbit | SEMS with 125I loaded | To evaluate radiotolerance | Caused epithelial hyperplasia and stricture | [90] |
Canine stricture | New covered SEMS | To test the antimigration | Half of stents migrated | [91] |
Mongrel dogs | New nitinol stent | Anti-postcaustic stricture | Better than unstented group | [92] |
Bama mini-pig | Nitinol stents loaded 5-FU or Paclitaxel (PTX) | To investigate tissue response; Drug release | Severe tissue response at the ends; highest drug concentrations in esophagus | [59, 60] |
New Zealand rabbits | magnetocaloric nitinol stent with PTX | Drug eluting Release | biocompatible and safe | [93] |
Healthy beagle dogs | Covered SEMS | Evaluate safety | No significant radiation toxicity | [94] |
Benign dog cardia stricture | paclitaxel or rapamycin-eluting stent | Observe inflammatory reaction | Drug-eluting stent had better outcomes | [95] |
A stricture model of rabbit | Three “piece” of SEMS with PLGA treads | Safety of the stent | The degradable part of the stent degraded; stent migrated | [96, 97] |
Mini pig | Full covered SEMS | to evaluate the clinical feasibility | Easy deployment; | [82, 98] |
Refractory benign strictures in dogs | SEMS, SEPS, BD | To evaluate the complications | 50% dogs had complications | [99] |
Pig stricture model | ELLA-CS); PLA/PCL BD stent |
To treat stricture | Did not prevent high-grade stricture formation. | [100, 101] |
Rabbit model. | IN-1233–eluting covered stents | To investigate the efficacy | decreased tissue hyperplasia |
[88] |
Dog model | PCDL BD stent | To treat stenosis | The stent recovered its initial shape in vivo | [102] |
Malignant rabbit models | SEMS, drug-eluting stent | To image cancer tissue, and treat | Successful in establishing a malignant esophagostenosis model in rabbits |
[7, 81, 103] |